Search for a clinical trial
Other search option(s)
74 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
AUSTRIA
SALZBURG
SALZBURG
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Innere Medizin III
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase Ib, open-label, dose-finding study of the JAK inhibitor INC424 tablets administered orally to patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) and baseline platelet counts > 50 x109/L and <100 x109/L - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
FREEDOM2: A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS - intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
MOMENTUM: A Randomized, Double-Blind, Phase 3 Study of Momelotinib vs Danazol in Symptomatic, Anemic Subjects With Previously JAKi Treated Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
TRANSFORM-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
AUSTRIA
WIEN
WIEN
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis - AT
Hanusch Krankenhaus
3. Medizinische Abteilung (Hämatologie und Onkologie)
BELGIUM
OOST-VLAANDEREN
GENT
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - BE
Ghent University Hospital - UZ Gent
Dienst Hematologie
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
RESUME - A phase-3, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to compare efficacy and safety of pomalidomide in subjects with myeloproliferative neoplasm -associated myelofibrosis and red blood cell-transfusion-dependence - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A randomized controlled phase III study of oral Pacritinib versus best available therapy in patients with Primary Myelofibrosis, Post-Polycythemia vera Myelofibrosis, or Post-Essential thrombocythemia Myelofibrosis - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis - FR
Institution: Information not provided - FR
GERMANY
Baden-Württemberg
HEIDELBERG
MPN-SG 01-09 (MPN Pomalidomide): Multicenter Phase II Study with Pomalidomide in patients with Myeloproliferative Neoplasms in fibrotic Stage
Nationales Centrum für Tumorerkrankungen (NCT)
Nationales Centrum für Tumorerkrankungen (CCC) Heidelberg
GERMANY
Baden-Württemberg
ULM
POMINC (MPN-SG 02-12): A Phase-Ib/II study of Ruxolitinib and Pomalidomide combination therapy in patients with primary and secondary Myelofibrosis
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
GERMANY
Bayern
MÜNCHEN
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - DE
Klinikum rechts der Isar der Technischen Universität München
GERMANY
Hamburg
HAMBURG
Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02 study) - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation
GERMANY
Niedersachsen
HANNOVER
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - DE
Medizinische Hochschule Hannover
Medizinische Hochschule Hannover (MHH)
GERMANY
Nordrhein-Westfalen
AACHEN
A Phase Ib/II, open-label, multicenter, dose-finding study to assess the safety and efficacy of the oral combination of LDE225 and INC424 (Ruxolitinib) in patients with Myelofibrosis - DE
Universitätsklinikum Aachen
Klinik für Onkologie, Hämatologie und Stammzelltransplantation (Med. Klinik IV)
GERMANY
Nordrhein-Westfalen
DÜSSELDORF
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - DE
Universitätsklinikum Düsseldorf
GERMANY
Nordrhein-Westfalen
MINDEN
JHTB(a): A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms - DE
Johannes Wesling Klinikum Minden
Klinik für Hämatologie, Onkologie und Palliativmedizin
GERMANY
Rheinland-Pfalz
MAINZ
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - DE
Universitätsmedizin Mainz
GERMANY
Sachsen
DRESDEN
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
GERMANY
Sachsen
LEIPZIG
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - DE
Universitätsklinikum Leipzig AöR
UCCL - Universitäres Krebszentrum Leipzig
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase 3b, Open Label, Single-arm Rollover Study to Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials - IT
Institution: Information not provided - IT
SPAIN
Andalucía
MÁLAGA
TRANSFORM-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis - ES
Hospital Regional Universitario de Málaga - Hospital General
SPAIN
Andalucía
MÁLAGA
TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis - ES
Hospital Universitario Virgen de la Victoria
SPAIN
Andalucía
MÁLAGA
An open-label, phase 2a/2b study of KRT-232 in subjects with primary myelofibrosis (PMF), post-polycythemia vera MF (Post-PV-MF), or post-essential thrombocythemia MF (Post-ET-MF) who have failed ruxolitinib - ES
Hospital Universitario Virgen de la Victoria
Unidad de Hematología
SPAIN
Andalucía
SEVILLA
TRANSFORM-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis - ES
Hospital Universitario Virgen del Rocío
SPAIN
Aragón
ZARAGOZA
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) (Phase II) - ES
Hospital Quirónsalud Zaragoza
Servicio de Hematología
SPAIN
Canarias
LAS PALMAS
TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis - ES
Hospital Universitario de Gran Canaria Dr. Negrín
SPAIN
Canarias
LAS PALMAS
TRANSFORM-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis - ES
Hospital Universitario de Gran Canaria Dr. Negrín
SPAIN
Canarias
LAS PALMAS
An open-label, phase 2a/2b study of KRT-232 in subjects with primary myelofibrosis (PMF), post-polycythemia vera MF (Post-PV-MF), or post-essential thrombocythemia MF (Post-ET-MF) who have failed ruxolitinib - ES
Hospital Universitario de Gran Canaria Dr. Negrín
Servicio de Hematología
SPAIN
Castilla - León
SALAMANCA
TRANSFORM-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis - ES
Hospital Clínico Universitario de Salamanca
SPAIN
Castilla - León
SALAMANCA
An open-label, phase 2a/2b study of KRT-232 in subjects with primary myelofibrosis (PMF), post-polycythemia vera MF (Post-PV-MF), or post-essential thrombocythemia MF (Post-ET-MF) who have failed ruxolitinib - ES
Hospital Clínico Universitario de Salamanca
Servicio de Hematología
SPAIN
Cataluña
BADALONA
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) (Phase II) - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica
SPAIN
Cataluña
BADALONA
An open-label, phase 2a/2b study of KRT-232 in subjects with primary myelofibrosis (PMF), post-polycythemia vera MF (Post-PV-MF), or post-essential thrombocythemia MF (Post-ET-MF) who have failed ruxolitinib - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica
SPAIN
Cataluña
BARCELONA
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) (Phase II) - ES
Hospital Clínic de Barcelona
Servicio de Hematología
SPAIN
Cataluña
BARCELONA
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) (Phase II) - ES
Hospital Universitari Vall d'Hebron
Servicio de Hematología y Hemoterapia
SPAIN
Cataluña
BARCELONA
SPAIN
Cataluña
BARCELONA
SPAIN
Comunidad Valenciana
VALENCIA
TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis - ES
Hospital Clínico Universitario de Valencia
SPAIN
Comunidad Valenciana
VALENCIA
TRANSFORM-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis - ES
Hospital Clínico Universitario de Valencia
SPAIN
Comunidad Valenciana
VALENCIA
An open-label, phase 2a/2b study of KRT-232 in subjects with primary myelofibrosis (PMF), post-polycythemia vera MF (Post-PV-MF), or post-essential thrombocythemia MF (Post-ET-MF) who have failed ruxolitinib - ES
Hospital Clínico Universitario de Valencia
Servicio de Hematología
SPAIN
Galicia
SANTIAGO DE COMPOSTELA
TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis - ES
Hospital Clínico Universitario de Santiago
SPAIN
Galicia
SANTIAGO DE COMPOSTELA
TRANSFORM-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis - ES
Hospital Clínico Universitario de Santiago
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2 Study of LY278544 in Patients With Myeloproliferative Neoplasms - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
FREEDOM2: A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS - intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
MOMENTUM: A Randomized, Double-Blind, Phase 3 Study of Momelotinib vs Danazol in Symptomatic, Anemic Subjects With Previously JAKi Treated Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
REFINE: A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
PACIFICA Phase 3: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000) - ES
Institution: Information not provided - ES
SPAIN
Madrid
MADRID
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) (Phase II) - ES
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
An open-label, phase 2a/2b study of KRT-232 in subjects with primary myelofibrosis (PMF), post-polycythemia vera MF (Post-PV-MF), or post-essential thrombocythemia MF (Post-ET-MF) who have failed ruxolitinib - ES
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MAJADAHONDA
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) (Phase II) - ES
Hospital Universitario Puerta de Hierro - Majadahonda
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MAJADAHONDA
An open-label, phase 2a/2b study of KRT-232 in subjects with primary myelofibrosis (PMF), post-polycythemia vera MF (Post-PV-MF), or post-essential thrombocythemia MF (Post-ET-MF) who have failed ruxolitinib - ES
Hospital Universitario Puerta de Hierro - Majadahonda
Servicio de Hematología y Hemoterapia
SPAIN
Navarra
PAMPLONA
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) (Phase II) - ES
Clínica Universidad de Navarra
Servicio de Hematología y Hemoterapia
UNITED KINGDOM
South Glamorgan
CARDIFF
Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)GB
University Hospital of Wales
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib - US
Institution: Information not provided - US
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
PAC203: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib - GB
Institution: Information not provided - US
UNITED STATES
Washington
SEATTLE
FRANCE
ILE-DE-FRANCE
PARIS
RACE : A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients (Phase III) - FR
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service d'Hématologie-Greffe
GERMANY
Baden-Württemberg
ULM
EMAA: Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A (Phase II/III) - DE
DRK Baden-Württemberg/ Hessen
Institut für Klinische Transfusionsmedizin und Immungenetik Ulm
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
RACE: A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients - IT
Institution: Information not provided - IT
UNITED KINGDOM
Greater London
LONDON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
Multinational clinical trial(s)
SWITZERLAND
Suisse Alémanique
BASEL
REALISE: A Multicenter Phase II, Open Label, Single Arm Study to Evaluate the Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients
Novartis Pharma Services AG
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
The COMFORT-II Trial: Randomized Study of INCB018424 Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis (Phase III) (coordination)
Institution: Information not provided - CH
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis
Institution: Information not provided - CH
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
JUMP: An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Institution: Information not provided - CH
UNITED STATES
Delaware
WILMINGTON
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Incyte Corporation
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
PAC203: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
Institution: Information not provided - US
UNITED STATES
Washington
SEATTLE
UNITED STATES
Texas
HOUSTON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.
SPAIN
Madrid
COLMENAR VIEJO